<DOC>
	<DOC>NCT01964963</DOC>
	<brief_summary>The purpose of this study is to examine the safety and efficacy of long-term treatment with alogliptin (Nesina) in patients with mild type 2 diabetes mellitus in the routine clinical setting.</brief_summary>
	<brief_title>Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This is a special drug use surveillance on long-term use of alogliptin, designed to investigate the safety and efficacy of treatment with alogliptin in patients with mild type 2 diabetes mellitus in the routine clinical setting. Participants will be patients with mild type 2 diabetes mellitus. The planned sample size is 20,000. The usual adult dosage for oral use is 1 alogliptin tablet (25 mg of alogliptin) once daily.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>Patients with HbA1c (JDS value) â‰¤7.0% at the time of enrolment (within 3 months before initiation of Nesina therapy), regardless of the use of antidiabetic medication. Patients contraindicated for Nesina 1. Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus. 2. Patients with severe infection, pre or postoperative patients, or patients with serious traumatic injury. 3. Patients with a history of hypersensitivity to any ingredient of Nesina.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>